These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 34752714)

  • 1. Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
    Mannelli P; Douaihy AB; Zavod A; Legedza A; Akerman SC; Sullivan MA
    Am J Drug Alcohol Abuse; 2021 Nov; 47(6):753-759. PubMed ID: 34752714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
    Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
    [No Abstract]   [Full Text] [Related]  

  • 5. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
    Kosten T; Aharonovich E; Nangia N; Zavod A; Akerman SC; Lopez-Bresnahan M; Sullivan MA
    Addict Behav; 2020 Dec; 111():106538. PubMed ID: 32777606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
    Mannelli P; Douaihy AB; Akerman SC; Legedza A; Fratantonio J; Zavod A; Sullivan MA
    Am J Addict; 2022 Mar; 31(2):142-147. PubMed ID: 35137481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants.
    Hall OT; Entrup P; Farabee K; Qin H; Rizvi H; Rausch J; Felkel WC; Teater J
    Subst Use Misuse; 2024; 59(2):312-315. PubMed ID: 37861246
    [No Abstract]   [Full Text] [Related]  

  • 8. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
    Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
    Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.
    Montgomery L; Winhusen T; Scodes J; Pavlicova M; Twitty D; Campbell ANC; Wang AL; Nunes EV; Rotrosen J
    J Subst Abuse Treat; 2021 Nov; 130():108489. PubMed ID: 34118716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.
    Greiner MG; Shulman M; Scodes J; Choo TH; Pavlicova M; Opara O; Campbell ANC; Novo P; Fishman M; Lee JD; Rotrosen J; Nunes EV
    Subst Use Misuse; 2022; 57(11):1732-1742. PubMed ID: 35975917
    [No Abstract]   [Full Text] [Related]  

  • 11. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
    Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
    J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
    Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
    Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.
    Mariani JJ; Dobbins RL; Heath A; Gray F; Hassman H
    Am J Addict; 2024 Jan; 33(1):8-14. PubMed ID: 37936553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
    Levin FR; Mariani JJ; Pavlicova M; Choi CJ; Basaraba C; Mahony AL; Brooks DJ; Naqvi N; Bisaga A
    Drug Alcohol Depend; 2021 Feb; 219():108482. PubMed ID: 33418204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial.
    Shulman M; Greiner MG; Tafessu HM; Opara O; Ohrtman K; Potter K; Hefner K; Jelstrom E; Rosenthal RN; Wenzel K; Fishman M; Rotrosen J; Ghitza UE; Nunes EV; Bisaga A
    JAMA Netw Open; 2024 May; 7(5):e249744. PubMed ID: 38717773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful administration of extended-release buprenorphine in the emergency department.
    LeSaint KT; Kendric KJ; Logan AA
    Am J Emerg Med; 2024 Oct; 84():189.e1-189.e3. PubMed ID: 39089938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Maintenance Therapeutic for Opioid Use Disorder.
    Youngblood B; Li K; Gehlert DR; Medina JC; Schwartz N
    J Pharmacol Exp Ther; 2021 Aug; 378(2):133-145. PubMed ID: 34011529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 48-hour Induction of Transdermal Buprenorphine to Extended-release Buprenorphine.
    Azar P; Wong JSH; Mathew N; Ignaszewski MJ; Partovi N; Krausz RM; Ajidahun A; Thotakura S; Harris M; Barrios R; Montaner JSG; Maharaj AR
    J Addict Med; 2024 Jan-Feb 01; 18(1):82-85. PubMed ID: 37847573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorder.
    Mariani JJ; Basaraba C; Pavlicova M; Alschuler DM; Brooks DJ; Mahony AL; Brezing C; Naqvi NH; Levin FR
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):618-629. PubMed ID: 37791817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.